Khan, Mohammad Ashrafuddin El-Gamal, Mohammed I. Tarazi, Hamadeh Choi, Hong Seok Oh, Chang-Hyun 2024-01-20T02:34:13Z 2024-01-20T02:34:13Z 2021-09-05 2016-12 1756-8919 https://pubs.kist.re.kr/handle/201004/123348 Background: Inhibition of V600E-B-RAF kinase represents a potential avenue for melanoma treatment. Herein, a series of 1,3,4-triarylpyrazoles possessing amide linker were designed, synthesized and evaluated for RAF kinase inhibition. Results: Compounds 1d and 1f were more potent than sorafenib against A375 cell line, and their selectivity indexes toward A375 than HS27 fibroblasts were 25.43 and 45.83, respectively. Compound 1f was more potent against the melanoma cell lines with B-RAF V600E mutation than melanoma cells with NRAS mutation and normal skin epithelial cells. Compounds 1d and 1f showed strong potency and selectivity against V600E-B-RAF kinase with IC50 values of 3.80 and 2.98 nM, respectively. Molecular docking studies revealed their binding mode. Conclusion: Potent and selective V600E-B-RAF antimelanoma agents were discovered. English FUTURE SCI LTD ANTITUMOR-ACTIVITY SIGNALING PATHWAY BRAF INHIBITION B-RAF CANCER MUTATIONS DIAGNOSIS THERAPY LIGANDS DOCKING Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells Article 10.4155/fmc-2016-0057 1 FUTURE MEDICINAL CHEMISTRY, v.8, no.18, pp.2197 - 2211 FUTURE MEDICINAL CHEMISTRY 8 18 2197 2211 scie scopus 000389449800005 2-s2.0-84999269045 Chemistry, Medicinal Pharmacology & Pharmacy Article ANTITUMOR-ACTIVITY SIGNALING PATHWAY BRAF INHIBITION B-RAF CANCER MUTATIONS DIAGNOSIS THERAPY LIGANDS DOCKING A375 docking melanoma pyrazole RAF kinase